dIntermittent three-times-weekly antibiotic therapy is recommended for the initial treatment of patients with noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease. Although some experts recommend switching from intermittent to daily therapy for patients whose sputum has persistent positive cultures after intermittent therapy, the clinical efficacy of these modifications is unknown. Of 20 patients whose sputum had persistent positive cultures after 12 months of intermittent antibiotic therapy, specimens from 6 patients (30%) achieved a negative culture after a change to daily therapy.
Mycobacterium avium complex lung disease (MAC-LD) is the most common form of lung disease caused by nontuberculous mycobacteria (NTM), and the prevalence of MAC-LD is increasing worldwide (1-12). MAC-LD can present as the upper lobe fibrocavitary form, which occurs primarily in men with underlying lung disease such as previous pulmonary tuberculosis, or as the nodular bronchiectatic (NB) form, which occurs primarily in women without other underlying lung disease (13-15).Intermittent three-times-weekly therapy, which consists of a macrolide (clarithromycin [CLR] or azithromycin [AZM]), rifampin (RIF), and ethambutol (EMB), is recommended for the initial treatment of noncavitary NB MAC-LD (16). After at least 12 months of this intermittent antibiotic therapy, however, sputum culture conversion fails in about 15% to 25% of patients (17,18). Some experts recommended modifications of the first-line therapy, such as switching from intermittent therapy to daily therapy, for these patients (19). However, there are no data in the literature regarding the clinical efficacy of these modifications in patients with refractory NB MAC-LD. The objective of the present study was to evaluate the effects of switching from intermittent therapy to daily therapy in noncavitary NB MAC-LD patients whose sputum failed culture conversion after at least 12 months of initial intermittent antibiotic therapy.We recently reported the treatment outcomes of 118 treatment-naive patients with noncavitary NB MAC-LD who initiated standard intermittent antibiotic therapy (18). The regimen for the intermittent therapy included the following components administered three times weekly: 500 mg of AZM or 1,000 mg of CLR, EMB at 25 mg/kg of body weight, and 600 mg of RIF. Of these patients, 79 patients (67%) achieved successful sputum culture conversion and 39 patients (33%) had unfavorable outcomes, including 13 patients with early discontinuation of antibiotic therapy and 26 patients whose sputum failed to convert to negative cultures despite 12 months of intermittent antibiotic therapy (18).Of these 26 patients, 1 patient was transferred to another hospital, and 25 patients continued antibiotic therapy in our institution; intermittent therapy continued in 4 patients (16%), and intermittent therapy was switched to daily therapy in 21 patients (84%). The modifications of antibiotic therapy in these 21 patients were at the discretion of the attending p...